Surgical Treatment of Hilar Cholangiocarcinoma: Minor or Major Liver Resection?

This study has been completed.

First Received: August 8, 2008 Last Updated: October 17, 2008 History of Changes

Sponsors and Collaborators:	Huazhong University of Science and Technology Ministry of Health, China "Hepatic Surgery Clinical Research Centre of Hubei, China"
Information provided by:	Huazhong University of Science and Technology
ClinicalTrials.gov Identifier:	NCT00733200

Purpose

The investigators conducted a prospective study to determine the safety and efficacy of minor and major hepatectomy selected by predetermined criteria in 138 patients with hilar cholangiocarcinoma. In selected patients, minor liver resection was a good treatment.

Condition	Intervention
Cholangiocarcinoma Surgical Treatment Hepatectomy	Procedure: Minor or Major Liver Resection

Study Type:	Interventional
Official Title:	Surgical Treatment of Hilar Cholangiocarcinoma: Minor or Major Liver Resection?

Resource links provided by NLM:

MedlinePlus related topics: Surgery

U.S. FDA Resources

Further study details as provided by Huazhong University of Science and Technology:

Primary Outcome Measures:

On multivariate analysis, prognostic factors significantly impacted on long-term survival were UICC tumor stage and histopathologic grade.

Arms	Assigned Interventions
Control group: No Intervention	Procedure: Minor or Major Liver Resection

Detailed Description:

Objective: To determine the safety and efficacy of minor and major hepatectomy selected by predetermined criteria in patients with hilar cholangiocarcinoma (HC). Summary Background Data: For HC treated with hepatectomy, the extent of liver resection remains controversial despite extensive studies. Methods: From January 2000 to December 2007, we prospectively studied patients who received surgical treatment for HC. Of the 187 patients who were surgically treated, 138 (73.8%) underwent resection with a curative intent.

Minor hepatectomy was carried out in 93 patients who had Bismuth-Corlette types I, II and III HC without hepatic artery/portal vein invasion; and major hepatectomy in 45 patients who had type III HC with hepatic artery/portal vein invasion, or type IV HC.

Eligibility

Ages Eligible for Study:	26 Years to 72 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Criteria for resectability were absence of peritoneal or liver metastases, tumor extension to beyond secondary biliary branches bilaterally, tumor extension to secondary portal venous branches bilaterally

Exclusion Criteria:

not in accordance with the above criteria

Contacts and Locations

No Contacts or Locations Provided

More Information

No publications provided

Study ID Numbers:	chenxp002
Study First Received:	August 8, 2008
Last Updated:	October 17, 2008
ClinicalTrials.gov Identifier:	NCT00733200 History of Changes
Health Authority:	China: State Food and Drug Administration

Keywords provided by Huazhong University of Science and Technology:

Minor Liver Resection
Major Liver Resection
Hilar

Study placed in the following topic categories:

Cholangiocarcinoma
Adenocarcinoma
Neoplasms, Glandular and Epithelial
Carcinoma

Additional relevant MeSH terms:

Cholangiocarcinoma
Neoplasms
Neoplasms by Histologic Type

Adenocarcinoma
Neoplasms, Glandular and Epithelial
Carcinoma

ClinicalTrials.gov processed this record on August 26, 2009